Exemptia 40 mg Injection
Exemptia 40 mg Injection Exemptia contains Adalimumab, a recombinant human IgG1 monoclonal antibody. It works by specifically binding to tumor necrosis factor-alpha (TNF-alpha) and neutralizing its biological function by blocking its interaction with cell surface TNF receptors. This reduces the inflammatory cascades and tissue destruction associated with autoimmune diseases. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis.
| Brand | Exemptia |
| Storage Temperature | Store between 2°C to 8°C (Refrigerate, Do not freeze, Protect from light) |
| Prescription Needed | Yes |
| Composition | Adalimumab |
| Strength | 40 mg / 0.8 mL |
| Form | Solution for Injection |
| Pack Size | 1 Pre-filled Syringe (0.8 mL) |
| Packaging | Single-dose pre-filled syringe |
| Country of Origin | Made In India |
| Manufacturer | Zydus Lifesciences Ltd. (Zydus Cadila) |
Exemptia 40 mg Injection
Exemptia 40 mg Injection Exemptia contains Adalimumab, a recombinant human IgG1 monoclonal antibody. It works by specifically binding to tumor necrosis factor-alpha (TNF-alpha) and neutralizing its biological function by blocking its interaction with cell surface TNF receptors. This reduces the inflammatory cascades and tissue destruction associated with autoimmune diseases. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis.
